Sai Parenterals Limited

As of September 30, 2025, Sai Parenterals Limited has 44.18M shares outstanding.

As of September 30, 2025, Sai Parenterals Limited maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 103.32, indicating elevated leverage, while an interest coverage ratio of 1.67 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2025. The company generates approximately 11.25M in revenue per employee across its workforce of 269.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended September 30, 2025, Sai Parenterals Limited recorded an income tax benefit of -7.89M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 8.64M, leaving 16.53M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026.

Over the twelve months ended September 30, 2025, Sai Parenterals Limited generated 3.03B in revenue and converted that into 16.53M in net income, yielding earnings per share of 0.37. EBITDA reached 322.31M, while operating income came in at 176.18M.

As of September 30, 2025, Sai Parenterals Limited holds 524.38M in cash and equivalents against 2.27B in total debt, resulting in a net debt position of 1.73B. Total book value stands at 2.11B, with working capital of 1.47B providing operational flexibility.

Over the twelve months ended September 30, 2025, Sai Parenterals Limited posted a gross margin of 41.28, reflecting its pricing power and cost economics. The operating margin of 5.82 and net profit margin of 0.55 provide insight into operational efficiency.